DXCM
DEXCOM INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 7 to May 15 ▼ 2 sells: Michael McCaul, Ro Khanna sold $1,001 - $15,000, last disclosed Jun 11
- Jun 3 to Jun 4 ▼ 2 days of insider sells: $722.6K by 1 insider, avg $73.56
- Jun 30 ▲ 4 funds open new positions (13F)
- Jul 15 to Jul 20 ▼ 2 days of insider sells: $2.2M by 2 insiders, avg $76.21
- Jul 31 to Aug 3 ▼ 2 days of insider sells: $330.6K by 1 insider, avg $82.66
- Aug 12 to Aug 27 ▼ 4 days of insider sells: $2.9M by 4 insiders, avg $89.92
- Sep 10 to Sep 15 ▼ 3 days of insider sells: $1.1M by 3 insiders, avg $83.83
- Sep 28 ▼ 1 insider sell $221.0K at $86.15
- Oct 7 Barclays initiates
- Oct 15 ▼ 1 insider sell $145.3K at $85.48
- Oct 27 ▼ 1 insider sell $201.7K at $78.62
- Oct 29 ▲ Dexcom reported Q3 2026 revenue of $1.344B (up 11% YoY), above the $…
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $12.1M.
- InstitutionsBULLISH
Q2 2026: 60 added (4 new), 40 trimmed or exited. Largest new: Capitolis Liquid Global Markets $44.8M, Capital International Investors $44.6M.
- AnalystsBULLISH
32 of 36 rate it Buy or better. Median target $96.50 (+18%).
- Short sellersSTEADY
Short interest +1.6% to 15.93M shares. 2.8 days to cover, ≈4.3% of shares.
- TrendDOWNTREND
3% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 24.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $462.9M |
| UBS Group AG | ADD | $408.5M |
| Castle Hook Partners LP | DOUBLED | $260.7M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $240.9M |
| JPMORGAN CHASE & CO | TRIM | $232.7M |
| DEUTSCHE BANK AG\ | TRIM | $164.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $152.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $150.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
36 analystsPrice is inside the target range. Median implies +18%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 30, 2026 | UBS MAINTAIN | Buy |
| Oct 30, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 30, 2026 | JP Morgan MAINTAIN | Neutral |
| Oct 30, 2026 | Barclays MAINTAIN | Overweight |
| Oct 30, 2026 | StoneX MAINTAIN | Buy |
| Oct 12, 2026 | BTIG MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Leach Jacob Steven President, CEO, and Director Nov 8, 2026 | TAX W/H | $115.2K |
Brown Michael Jon EVP Chief Legal Compliance Off Nov 8, 2026 | TAX W/H | $115.2K |
Stern Sadie EVP Chief People & Culture Off Nov 8, 2026 | TAX W/H | $115.2K |
Sylvain Jereme M EVP, COO & CFO Nov 8, 2026 | TAX W/H | $115.2K |
Ashley Euan A. Director Oct 30, 2026 | GIFT | 2,389 sh |
Stern Sadie EVP Chief People & Culture Off Oct 27, 2026 | SELL | $201.7K |
Brown Michael Jon EVP Chief Legal Compliance Off Oct 15, 2026 | SELL | $145.3K |
Stern Sadie EVP Chief People & Culture Off Sep 28, 2026 | SELL | $221.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 1 bullish · 1 bearish · 1 mixed · 13 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corp disclosed a 5% passive beneficial ownership stake in Dexcom Inc via Schedule…
State Street's passive 5% stake is a routine institutional disclosure with no activist implications. Monitor for any future 13D conversion or stake changes in subsequent filings, but no immediate…
- NEUTRAL INST-CLUSTERNov 2, 2026
In Q3 2026, three small asset managers added DXCM positions totaling $8.7M while four larger asset…
The cluster shows divergence between small accumulators and large trimmers. Monitor upcoming 13F filings for Q4 to see if the selling trend continues or reverses, particularly from Assenagon and…
- BULLISH 8-KOct 29, 2026
Dexcom reported Q3 2026 revenue of $1.344B (up 11% YoY), above the $1.33B consensus, and non-GAAP…
The raised revenue guidance midpoint and expanded operating margins signal accelerating operational leverage. The $1.0B buyback adds a capital return catalyst. Monitor the G7 15 Day international…
- NEUTRAL 144Oct 27, 2026
Sadie Stern, an officer of Dexcom, filed a Form 144 notice of intent to sell 2,565 shares of…
The sale is small relative to market cap and appears to be a routine diversification trade by an officer following restricted stock vesting. No material signal for the stock; monitor for any larger…
All DXCM filing & press-release reports (16)
- SC 13G reportNov 10, 2026
- INST-CLUSTER reportNov 2, 2026
- 8-K reportOct 29, 2026
- 144 reportOct 27, 2026
- CLUSTER reportSep 16, 2026
- 8-K reportSep 14, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 17, 2026
- CLUSTER reportJul 21, 2026
- CLUSTER reportJun 17, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 19, 2026
- DEFA14A reportApr 15, 2026
- INST-CLUSTER reportFeb 28, 2026